GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management

Torsten Zuberbier; Antonella Muraro; Ulugbek Nurmatov; Stefania Arasi; Katarina Stevanovic; Aikaterini Anagnostou; Roberta Bonaguro; Sharon Chinthrajah; Gideon Lack; Alessandro Fiocchi; Thuy My Le; Paul Turner; Montserrat Alvaro Lozano; Elizabeth Angier; Simona Barni; Phillippe Bégin; Barbara Ballmer-Weber; Victoria Cardona; Carsten Bindslev-Jensen; Antonella Cianferoni; Nicolette de Jong; Debra de Silva; Antoine Deschildre; Audrey Dunn Galvin; Motohiro Ebisawa; David M. Fleischer; Jennifer Gerdts; Mattia Giovannini; Josefine Gradman; Susanne Halken; Syed Hasan Arshad; Ekaterina Khaleva; Susanne Lau; Richard Loh; Mika J. Mäkelä; Mary Jane Marchisotto; Laura Morandini; Charlotte G. Mortz; Caroline Nilsson; Anna Nowak-Wegrzyn; Marcia Podestà; Lars K. Poulsen; Graham Roberts; Pablo Rodríguez del Río; Hugh A. Sampson; Angel Sánchez; Sabine Schnadt; Peter K. Smith; Hania Szajewska; Natasa Teovska Mitrevska; Alice Toniolo; Carina Venter; Amena Warner; Gary W.K. Wong; Robert Wood; Margitta Worm

doi:10.1002/clt2.70002

GA²LEN ANACARE consensus statement: Potential of omalizumab in food allergy management

Torsten Zuberbier^*, Antonella Muraro, Ulugbek Nurmatov, Stefania Arasi, Katarina Stevanovic, Aikaterini Anagnostou, Roberta Bonaguro, Sharon Chinthrajah, Gideon Lack, Alessandro Fiocchi, Thuy My Le, Paul Turner, Montserrat Alvaro Lozano, Elizabeth Angier, Simona Barni, Phillippe Bégin, Barbara Ballmer-Weber, Victoria Cardona, Carsten Bindslev-Jensen, Antonella CianferoniNicolette de Jong, Debra de Silva, Antoine Deschildre, Audrey Dunn Galvin, Motohiro Ebisawa, David M. Fleischer, Jennifer Gerdts, Mattia Giovannini, Josefine Gradman, Susanne Halken, Syed Hasan Arshad, Ekaterina Khaleva, Susanne Lau, Richard Loh, Mika J. Mäkelä, Mary Jane Marchisotto, Laura Morandini, Charlotte G. Mortz, Caroline Nilsson, Anna Nowak-Wegrzyn, Marcia Podestà, Lars K. Poulsen, Graham Roberts, Pablo Rodríguez del Río, Hugh A. Sampson, Angel Sánchez, Sabine Schnadt, Peter K. Smith, Hania Szajewska, Natasa Teovska Mitrevska, Alice Toniolo, Carina Venter, Amena Warner, Gary W.K. Wong, Robert Wood, Margitta Worm

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

1 Downloads (Pure)

Abstract

Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA²LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.

Original language	English
Article number	e70002
Journal	Clinical and Translational Allergy
Volume	14
Issue number	11
DOIs	https://doi.org/10.1002/clt2.70002
Publication status	Published - Nov 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/clt2.70002Licence: CC BY

Clinical Translational All - 2024 - Zuberbier - GA2LEN ANACARE consensus statement Potential of omalizumab in foodFinal published version, 725 KBLicence: CC BY

Cite this

Zuberbier, T., Muraro, A., Nurmatov, U., Arasi, S., Stevanovic, K., Anagnostou, A., Bonaguro, R., Chinthrajah, S., Lack, G., Fiocchi, A., Le, T. M., Turner, P., Lozano, M. A., Angier, E., Barni, S., Bégin, P., Ballmer-Weber, B., Cardona, V., Bindslev-Jensen, C., ... Worm, M. (2024). GA²LEN ANACARE consensus statement: Potential of omalizumab in food allergy management. Clinical and Translational Allergy, 14(11), Article e70002. https://doi.org/10.1002/clt2.70002

@article{7899bf74258742599f0fa4dfd4c7ec60,

title = "GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management",

abstract = "Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.",

author = "Torsten Zuberbier and Antonella Muraro and Ulugbek Nurmatov and Stefania Arasi and Katarina Stevanovic and Aikaterini Anagnostou and Roberta Bonaguro and Sharon Chinthrajah and Gideon Lack and Alessandro Fiocchi and Le, {Thuy My} and Paul Turner and Lozano, {Montserrat Alvaro} and Elizabeth Angier and Simona Barni and Phillippe B{\'e}gin and Barbara Ballmer-Weber and Victoria Cardona and Carsten Bindslev-Jensen and Antonella Cianferoni and {de Jong}, Nicolette and {de Silva}, Debra and Antoine Deschildre and Galvin, {Audrey Dunn} and Motohiro Ebisawa and Fleischer, {David M.} and Jennifer Gerdts and Mattia Giovannini and Josefine Gradman and Susanne Halken and Arshad, {Syed Hasan} and Ekaterina Khaleva and Susanne Lau and Richard Loh and M{\"a}kel{\"a}, {Mika J.} and Marchisotto, {Mary Jane} and Laura Morandini and Mortz, {Charlotte G.} and Caroline Nilsson and Anna Nowak-Wegrzyn and Marcia Podest{\`a} and Poulsen, {Lars K.} and Graham Roberts and {Rodr{\'i}guez del R{\'i}o}, Pablo and Sampson, {Hugh A.} and Angel S{\'a}nchez and Sabine Schnadt and Smith, {Peter K.} and Hania Szajewska and Mitrevska, {Natasa Teovska} and Alice Toniolo and Carina Venter and Amena Warner and Wong, {Gary W.K.} and Robert Wood and Margitta Worm",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.",

year = "2024",

month = nov,

doi = "10.1002/clt2.70002",

language = "English",

volume = "14",

journal = "Clinical and Translational Allergy",

issn = "2045-7022",

publisher = "John Wiley & Sons Inc.",

number = "11",

}

Zuberbier, T, Muraro, A, Nurmatov, U, Arasi, S, Stevanovic, K, Anagnostou, A, Bonaguro, R, Chinthrajah, S, Lack, G, Fiocchi, A, Le, TM, Turner, P, Lozano, MA, Angier, E, Barni, S, Bégin, P, Ballmer-Weber, B, Cardona, V, Bindslev-Jensen, C, Cianferoni, A, de Jong, N, de Silva, D, Deschildre, A, Galvin, AD, Ebisawa, M, Fleischer, DM, Gerdts, J, Giovannini, M, Gradman, J, Halken, S, Arshad, SH, Khaleva, E, Lau, S, Loh, R, Mäkelä, MJ, Marchisotto, MJ, Morandini, L, Mortz, CG, Nilsson, C, Nowak-Wegrzyn, A, Podestà, M, Poulsen, LK, Roberts, G, Rodríguez del Río, P, Sampson, HA, Sánchez, A, Schnadt, S, Smith, PK, Szajewska, H, Mitrevska, NT, Toniolo, A, Venter, C, Warner, A, Wong, GWK, Wood, R & Worm, M 2024, 'GA²LEN ANACARE consensus statement: Potential of omalizumab in food allergy management', Clinical and Translational Allergy, vol. 14, no. 11, e70002. https://doi.org/10.1002/clt2.70002

TY - JOUR

T1 - GA2LEN ANACARE consensus statement

T2 - Potential of omalizumab in food allergy management

AU - Zuberbier, Torsten

AU - Muraro, Antonella

AU - Nurmatov, Ulugbek

AU - Arasi, Stefania

AU - Stevanovic, Katarina

AU - Anagnostou, Aikaterini

AU - Bonaguro, Roberta

AU - Chinthrajah, Sharon

AU - Lack, Gideon

AU - Fiocchi, Alessandro

AU - Le, Thuy My

AU - Turner, Paul

AU - Lozano, Montserrat Alvaro

AU - Angier, Elizabeth

AU - Barni, Simona

AU - Bégin, Phillippe

AU - Ballmer-Weber, Barbara

AU - Cardona, Victoria

AU - Bindslev-Jensen, Carsten

AU - Cianferoni, Antonella

AU - de Jong, Nicolette

AU - de Silva, Debra

AU - Deschildre, Antoine

AU - Galvin, Audrey Dunn

AU - Ebisawa, Motohiro

AU - Fleischer, David M.

AU - Gerdts, Jennifer

AU - Giovannini, Mattia

AU - Gradman, Josefine

AU - Halken, Susanne

AU - Arshad, Syed Hasan

AU - Khaleva, Ekaterina

AU - Lau, Susanne

AU - Loh, Richard

AU - Mäkelä, Mika J.

AU - Marchisotto, Mary Jane

AU - Morandini, Laura

AU - Mortz, Charlotte G.

AU - Nilsson, Caroline

AU - Nowak-Wegrzyn, Anna

AU - Podestà, Marcia

AU - Poulsen, Lars K.

AU - Roberts, Graham

AU - Rodríguez del Río, Pablo

AU - Sampson, Hugh A.

AU - Sánchez, Angel

AU - Schnadt, Sabine

AU - Smith, Peter K.

AU - Szajewska, Hania

AU - Mitrevska, Natasa Teovska

AU - Toniolo, Alice

AU - Venter, Carina

AU - Warner, Amena

AU - Wong, Gary W.K.

AU - Wood, Robert

AU - Worm, Margitta

PY - 2024/11

Y1 - 2024/11

N2 - Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.

AB - Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.

UR - http://www.scopus.com/inward/record.url?scp=85208227437&partnerID=8YFLogxK

U2 - 10.1002/clt2.70002

DO - 10.1002/clt2.70002

M3 - Review article

C2 - 39506193

AN - SCOPUS:85208227437

SN - 2045-7022

VL - 14

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

IS - 11

M1 - e70002

ER -